Thermo Fisher and University of California look to cut costs and speed up adoption of cell therapies

By Jane Byrne

- Last updated on GMT

© GettyImages/Maksim Tkachenko
© GettyImages/Maksim Tkachenko

Related tags reagents Software Cell therapy Thermo fisher scientific

Thermo Fisher Scientific Inc and the University of California, San Francisco (UCSF) have formed a alliance to accelerate the development and manufacturing of cell-based therapies.

Under the agreement, Thermo Fisher will build and operate a 44,000-square-foot, cell therapy development, manufacturing and collaboration center in leased space on UCSF's Mission Bay campus, which includes biomedical research facilities and hospitals.

The site will offer clinical and commercial cGMP cell therapy manufacturing services, along with associated technology development support, to UCSF and other partners.

Expected to open in 2022, the facility will also serve as a central location where customers and UCSF researchers will have access to Thermo Fisher's broad portfolio of Cell Therapy Systems (CTS) reagents, consumables, and fit-for-purpose instrumentation and compliant software.

In terms of how the partnership will speed up the adoption of cell therapies, a spokesperson for Thermo Fisher told BioPharma-Reporter:

“Cell therapy approaches have demonstrated positive results in a growing number of cancer patients, yet the ability to optimally manufacture cell therapies efficiently and at scale has hindered broader adoption. In collaboration with UCSF, Thermo Fisher will define performance and quality standards, standardize and automate workflows, decrease process variability, and innovate flexible, closed bench-to-clinic solutions for cell therapy applications.”

Improving patient access

By establishing cell therapy manufacturing close to the patient, UCSF is able to bring full cycle, clinical translational therapies for patients in need, she added.

“This combination will provide customers – from emerging biotechs to large pharma companies – with integrated, end-to-end solutions to reduce costs and accelerate adoption of cell therapies, ultimately improving patient access to these transformative treatments.”

Sam Hawgood, chancellor of UCSF, said breakthrough treatments using cell therapies are anticipated for many different diseases and conditions.  “Establishing cell therapy manufacturing in such close proximity to our scientists, clinicians and patients will enable UCSF to catalyze innovation in living therapeutics and use the resulting discoveries to benefit our patients."


Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us


View more